Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 5Melanoma 3Lymphoma 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Pancreatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Turcot syndrome 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1Colorectal Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 3toripalimab 2sintilimab 2Neoadjuvant Therapy 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1durvalumab 1denileukin diftitox 1danvatirsen 1camrelizumab 1avelumab 1atezolizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Turcot syndrome × denileukin diftitox × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡